<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03293992</url>
  </required_header>
  <id_info>
    <org_study_id>BP39863</org_study_id>
    <nct_id>NCT03293992</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Phase I, Multi-Center, Randomized, Adaptive, Investigator/Patient Masked, Multiple-Ascending Dose, Placebo and Active Comparator-Controlled Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Topical Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, multi-center, randomized, adaptive, investigator/patient-masked,
      placebo-controlled, parallel multiple-ascending dose study (Part A) with an extension
      including up to two selected doses from Part A and latanoprost 0.005% as active comparator
      (Part B).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 11, 2017</start_date>
  <completion_date type="Actual">December 21, 2017</completion_date>
  <primary_completion_date type="Actual">December 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, Severity, and Causal Relationship of Ocular and Systemic Adverse Events (AEs)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Abnormal Laboratory Findings</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Blood Pressure Abnormalities</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Pulse Rate Abnormalities</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Electrocardiogram (ECG) Findings</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mean Intraocular pressure (IOP) After 7 Days of Study Drug Administration</measure>
    <time_frame>7 days</time_frame>
    <description>IOP will be assessed by Goldman Applanation tonometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Intraocular pressure (IOP) at Matched Clock-Times After 7 Days of Study Drug Administration</measure>
    <time_frame>7 days</time_frame>
    <description>IOP will be assessed by Goldmann Applanation tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of RO7058584</measure>
    <time_frame>Up to Day 8</time_frame>
    <description>Cmax is the maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of RO7058584</measure>
    <time_frame>Up to Day 8</time_frame>
    <description>Tmax is the time to maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of RO7058584</measure>
    <time_frame>Up to Day 8</time_frame>
    <description>Ctrough is the concentration at the end of a dosing interval before the next dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24h of RO7058584</measure>
    <time_frame>Up to Day 8</time_frame>
    <description>AUC0-24h is the area under the plasma concentration versus time curve (AUC) from Time 0 to 24 h post-dose.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Glaucoma, Open-angle</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>0.01% RO7058584 or Matching Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1% RO7058584 or Matching Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1% RO7058584 or Matching Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RO7058584 and Latanoprost 0.005%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.01% RO7058584</intervention_name>
    <description>Once daily morning administration for 7 days</description>
    <arm_group_label>0.01% RO7058584 or Matching Placebo</arm_group_label>
    <arm_group_label>RO7058584 and Latanoprost 0.005%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% RO7058584</intervention_name>
    <description>Once daily morning administration for 7 days</description>
    <arm_group_label>0.1% RO7058584 or Matching Placebo</arm_group_label>
    <arm_group_label>RO7058584 and Latanoprost 0.005%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% RO7058584</intervention_name>
    <description>Once daily morning administration for 7 days</description>
    <arm_group_label>1% RO7058584 or Matching Placebo</arm_group_label>
    <arm_group_label>RO7058584 and Latanoprost 0.005%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Once daily morning administration for 7 days</description>
    <arm_group_label>0.01% RO7058584 or Matching Placebo</arm_group_label>
    <arm_group_label>0.1% RO7058584 or Matching Placebo</arm_group_label>
    <arm_group_label>1% RO7058584 or Matching Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost 0.005%</intervention_name>
    <description>Once daily morning or evening dosing</description>
    <arm_group_label>RO7058584 and Latanoprost 0.005%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 90 years of age inclusive, at the time of signing the informed consent form

          -  Confirmed diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma (POAG)
             in both eyes as determined by the investigator at screening

          -  Treatment-naïve participants or participants who are able to safely stop their
             Intraocular pressure (IOP)-lowering medication(s) prior to randomization according to
             the required minimum washout periods

          -  At baseline visit, IOP ≥ 24 millimeters of mercury (mmHg) in the morning (8:00 AM ±
             1h) and ≥ 22 mmHg in the afternoon (2:00 PM ± 1h) measurement in the same eye and ≤ 34
             mmHg at all timepoints in both eyes

          -  Best corrected logarithm of the minimum angle of resolution (logMAR) visual acuity
             score of 0.7 or better in each eye as measured by Early Treatment Diabetic Retinopathy
             Study (ETDRS) visual acuity test at screening

          -  Central corneal thickness (pachymetry) measurement 450 to 620 micrometers (μm) in both
             eyes at screening

          -  Cup-to-disc ratio ≤ 0.8 (both eyes) at screening

          -  Anterior chamber angle is open and non-occludable (both eyes) as confirmed by the
             investigator by gonioscopy examination at screening

        Exclusion Criteria:

          -  Advanced visual field defects

          -  Other forms of glaucoma than POAG or OHT

          -  Any abnormality preventing reliable applanation tonometry

          -  Any clinically significant corneal scarring, haze or opacity

          -  Uncooperativeness of the participant that restricts adequate examination of IOP,
             ocular fundus or anterior chamber

          -  Any presence or history of uveitis or other history of any ocular inflammatory
             disease.

          -  History or signs of penetrating ocular trauma

          -  Risk of visual field or visual acuity worsening in either eye as a consequence of
             glaucoma progression or consequence of participation in the trial or any other ocular
             disease, according to the investigator's best judgment

          -  History of any glaucoma surgery

          -  History of refractive surgery

          -  Any other intra-ocular surgery within six months of screening

          -  Any active ocular disease requiring treatment.

          -  Use of any listed prohibited medications

          -  Current enrollment or past participation within the last 30 days before the screening
             visit in any other clinical study involving an investigational study treatment or any
             other type of medical research

          -  Any participant who is the investigator or any sub-investigator, research assistant,
             pharmacist, study coordinator, other staff thereof, directly involved in the conduct
             of the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Eye Center</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sall Research Medical Center</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Med Res Inst</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye research foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Lions Eye Inst</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Centers Management, Inc. (Clayton Eye Center)</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Research Associates</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texan Eye/Keystone Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

